Anti-idiotypic Patents (Class 424/131.1)
  • Patent number: 9803014
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: October 31, 2017
    Assignee: Research Development Foundation
    Inventors: Beat Imhof, Christiane Ody, Thomas Matthes, Carmen Donate
  • Patent number: 9795618
    Abstract: Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: October 24, 2017
    Assignee: University of Cincinnati
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Patent number: 9783613
    Abstract: In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fc? receptor.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: October 10, 2017
    Assignee: IGEM Therapeutics Limited
    Inventors: Sophia Karagiannis, Andrew Beavil, Frank Nestle
  • Patent number: 9580504
    Abstract: Methods for treating specific populations of cancer patients, specifically patients suffering from cancer who undergo stem cell transplantation and were classified as positive by a pre-transplant metabolic imaging, by administering to the subject a therapeutically effective amount of a pidilizumab monoclonal antibody.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 28, 2017
    Assignee: CureTech Ltd.
    Inventors: Rinat Rotem-Yehudar, Michael Schickler
  • Patent number: 9573995
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 21, 2017
    Assignee: SCHOLAR ROCK, INC.
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Marie Straub
  • Patent number: 9527924
    Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: December 27, 2016
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Patent number: 9221911
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 29, 2015
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • Patent number: 9125893
    Abstract: The present invention relates to a highly concentrated solution preparation of antagonistic anti-CD40 antibody, in which occurrence of turbidity or insoluble foreign matter attributed to antibodies is suppressed to a level equivalent to that of the conventional low-concentration lyophilized preparation.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: September 8, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Ryosuke Endo, Tomoyoshi Ishikawa, Hiroyuki Suetomo
  • Patent number: 9102731
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 11, 2015
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Patent number: 9102722
    Abstract: Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: August 11, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
  • Patent number: 9101559
    Abstract: The present invention is directed to methods of preventing central nervous system leukemia, treating T-cell acute lymphoblastic leukemia, and treating immune system disorders associated with CCR7-CCL19 mediated signaling. Suitable therapeutic agents for inhibiting CCR7-CCL19 signaling and methods of identifying additional therapeutic agents useful in the methods of the present invention are also disclosed.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: August 11, 2015
    Assignee: New York University
    Inventors: Iannis Aifantis, Silvia Buonamici
  • Publication number: 20150147314
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 28, 2015
    Inventors: Wilfred Jefferies, Reinhard Gabathuler
  • Publication number: 20150132287
    Abstract: The present invention is directed to methods for modulating the Th/Th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the Th1/Th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Applicant: ENZO THERAPEUTICS, INC. C/O ENZO BIOCHEM, INC.
    Inventors: YARON ILAN, ERAN ELINAV
  • Publication number: 20150132286
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 14, 2015
    Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
  • Publication number: 20150125442
    Abstract: Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 7, 2015
    Inventors: Steven J. Burden, Wei Zhang, Maartje Huijbers, Johannes J. Verschuuren, Silvère M. van der Maarel
  • Patent number: 9017673
    Abstract: The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-?3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.
    Type: Grant
    Filed: June 11, 2004
    Date of Patent: April 28, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Michèle Floc'h Baudy, Olivier Busnel, Sylviane Muller
  • Publication number: 20150056182
    Abstract: The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved.
    Type: Application
    Filed: November 30, 2012
    Publication date: February 26, 2015
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Naoka Hironiwa
  • Publication number: 20150010535
    Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.
    Type: Application
    Filed: May 19, 2014
    Publication date: January 8, 2015
    Inventor: Bal Ram Singh
  • Publication number: 20140363422
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Application
    Filed: January 2, 2013
    Publication date: December 11, 2014
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
  • Patent number: 8883148
    Abstract: A method for treating, preventing or reducing the risk of joint destruction in a subject who suffers from a joint or musculoskeletal disease. The method comprises administering a histone deacetylase (HDAC) inhibitor or in conjunction with other agents to inhibit degradation and resorption of cartilage and bone in the joint.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: November 11, 2014
    Assignee: ASAN Laboratories Company (Cayman), Limited
    Inventor: Yih-Lin Chung
  • Publication number: 20140328922
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Publication number: 20140322199
    Abstract: The technology described herein is directed to methods of treating cardiovascular and metabolic disorders.
    Type: Application
    Filed: August 6, 2012
    Publication date: October 30, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Guo-Ping Shi
  • Patent number: 8846039
    Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: September 30, 2014
    Assignee: Asan Laboratories Company (Cayman), Limited
    Inventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
  • Publication number: 20140271618
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Application
    Filed: October 10, 2012
    Publication date: September 18, 2014
    Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., CCAM BIOTHERAPEUTICS LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • Publication number: 20140248211
    Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: INTENSITY THERAPEUTICS, INC.
    Inventor: Lewis H. Bender
  • Patent number: 8821874
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: September 2, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
  • Publication number: 20140242068
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 28, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Publication number: 20140234294
    Abstract: The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role.
    Type: Application
    Filed: December 24, 2013
    Publication date: August 21, 2014
    Applicant: Kobenhavns Universitet
    Inventors: Vladimir Berezin, Elisabeth Bock, Artur Kochoyan
  • Patent number: 8795669
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: August 5, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott Walsh, Daniel Dix
  • Publication number: 20140212408
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 31, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Publication number: 20140178362
    Abstract: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro.
    Type: Application
    Filed: July 1, 2013
    Publication date: June 26, 2014
    Applicant: CELERA CORPORATION
    Inventors: Charles E. BIRSE, Bruno DOMON, Steve RUBEN, Candy LEE
  • Patent number: 8758753
    Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: June 24, 2014
    Assignee: Centro de Inmunologia Molecular (CIM)
    Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
  • Publication number: 20140170134
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
    Type: Application
    Filed: August 15, 2012
    Publication date: June 19, 2014
    Applicant: The University of Chicago
    Inventors: Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carta Emolo, Andrea Dedent
  • Patent number: 8753629
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: June 17, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Publication number: 20140161792
    Abstract: The present invention relates to a rhamno-polysaccharide antigen from Enterococcus faecium clonal complex which is useful as a vaccine component for therapy and/or prophylaxis of bacterial infection.
    Type: Application
    Filed: May 25, 2012
    Publication date: June 12, 2014
    Applicants: FORSCHUNGSZENTRUM BORSTEL, UNIVERSIT TSKLINIKUM FREIBURG
    Inventors: Johannes Hübner, Christian Theilacker, Zbignew Kacynski, Otto Holst
  • Publication number: 20140134154
    Abstract: The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.
    Type: Application
    Filed: August 6, 2013
    Publication date: May 15, 2014
    Applicant: VANDERBILT UNIVERSITY
    Inventors: Paula R. Pohlmann, Ray Mernaugh, Carlos Arteaga
  • Publication number: 20140134155
    Abstract: The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumour diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 15, 2014
    Applicant: Technische Universität Dresden
    Inventor: Michael Bachmann
  • Publication number: 20140127199
    Abstract: The invention features compositions comprising agents that inhibit or reduce self-reactive IgE and/or basophils, and related methods of using the compositions for treating or preventing lupus, lupus nephritis, and lupus-related disorders.
    Type: Application
    Filed: November 24, 2010
    Publication date: May 8, 2014
    Applicant: The United States of America,as represented by the Secretary, Department of Health & Human Services
    Inventors: Juan Rivera, Nicolas Charles
  • Publication number: 20140115729
    Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 24, 2014
    Applicant: Genentech, Inc.
    Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
  • Publication number: 20140065100
    Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Fields
  • Publication number: 20140044702
    Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Application
    Filed: September 9, 2013
    Publication date: February 13, 2014
    Applicant: Genentech, Inc.
    Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
  • Publication number: 20140037615
    Abstract: The present invention relates to compositions, kits, and methods for preparing an autologous idiotype vaccine, or autologous anti-idiotype vaccine, for treatment of a B-cell malignancy based on the isotype(s) (class(es)) of immunoglobulins expressed by the malignancy; methods for treating B-cell malignancies; and methods for selecting a treatment for a subject having a B-cell malignancy.
    Type: Application
    Filed: August 12, 2011
    Publication date: February 6, 2014
    Applicant: BIOVEST INTERNATIONAL, INC.
    Inventors: Carlos F. Santos, Mihaela Popa-Mckiver, Amy M. McCord, Mark Hirschel
  • Patent number: 8642039
    Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: February 4, 2014
    Assignee: KaloBios Pharmaceuticals, INc.
    Inventor: Geoffrey T. Yarranton
  • Patent number: 8637567
    Abstract: This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: January 28, 2014
    Assignee: Neuren Pharmaceuticals Ltd.
    Inventors: Peter David Gluckman, Jian Guan, Mary-Anne Woodnorth, Margaret Anne Brimble
  • Publication number: 20130330323
    Abstract: In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 12, 2013
    Inventors: Robert J. Dunn, Marilyn R. Kehry
  • Publication number: 20130315892
    Abstract: The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.
    Type: Application
    Filed: June 7, 2013
    Publication date: November 28, 2013
    Inventors: ALESSANDRO MORETTA, ROBERTA CASTRICONI, CHRISTINA BOTTINO, LORENZO MORETTA
  • Publication number: 20130302315
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: June 14, 2013
    Publication date: November 14, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Publication number: 20130302314
    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 14, 2013
    Inventor: Academia Sinica
  • Publication number: 20130243750
    Abstract: This invention provides anti-IgE antibodies that bind to the M1? segment of a human IgE and their use in treating and preventing IgE-mediated disorders, as well as kits comprising the anti-IgE antibodies.
    Type: Application
    Filed: January 30, 2013
    Publication date: September 19, 2013
    Applicant: Genentech, Inc.
    Inventors: Heleen Scheerens, Jeffrey Mark Harris, John Matthews, Wendy Sue Putnam, X. Charlene Liao
  • Publication number: 20130243749
    Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 19, 2013
    Applicant: Dana Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir